Prescrire Int. 2000 Aug;9(48):112-3.
(1) Sertraline, a selective serotonin reuptake inhibitor (SSRI), is now licensed in France for the treatment of obsessive-compulsive disorder in adults. (2) In this indication the clinical file is of acceptable methodological quality, but it is incomplete: sertraline has not been compared with the other two serotonin reuptake inhibitors approved in obsessive-compulsive disorder, namely fluoxetine and paroxetine. (3) Three placebo-controlled trials have demonstrated the efficacy of sertraline in obsessive-compulsive disorder. (4) In a trial versus clomipramine, sertraline was no more effective in patients able to tolerate the drug, but the rate of treatment withdrawals for adverse events was higher on clomipramine.
（1）舍曲林是一种选择性5-羟色胺再摄取抑制剂（SSRI），目前在法国已获许可用于治疗成人强迫症。（2）在这一适应症方面，临床资料的方法学质量尚可，但并不完整：舍曲林尚未与另外两种已获批用于强迫症治疗的5-羟色胺再摄取抑制剂，即氟西汀和帕罗西汀进行对比。（3）三项安慰剂对照试验已证明舍曲林对强迫症有效。（4）在一项与氯米帕明对比的试验中，对于能够耐受该药的患者，舍曲林并不比氯米帕明更有效，但氯米帕明因不良事件导致的治疗中断率更高。
